|
Lower eyelid retraction associated with prior blepharoplasty, trauma or other conditions is a challenging problem. In this video Robert A. Goldberg, MD, demonstrates a technique for en-glove lysis of lower eyelid scar tissue that preserves the posterior lamellar and creates a space that can receive a dermis fat graft to restore the collapsed fat volume. View it
|
|
Allergan, Inc. announced that the FDA has approved Ozurdex (dexamethasone intravitreal implant) 0.7 mg, the first approved drug therapy for macular edema following branch retinal vein occlusion or central retinal vein occlusion. Read more
|
|
Robert Wise, MD, vice president of the division of standards and survey methods at the Joint Commission discusses the genesis of the Commission's updated position statement on sterilization practices, including its significance to ophthalmologists and proper technique to ensure compliance. Read more
|
|
Diamond Y. Tam, MD, reported at the 2009 ASCRS meeting one-year results from a retrospective study he and Ike Ahmed, MD, conducted comparing canaloplasty with trabeculectomy. They found that canaloplasty produced similar results to trabeculectomy; however, the non-penetrating surgery demonstrated a better safety profile. Read more
|
|
At the 2009 SOE Congress, Adnan Tufail, MD, of Moorfields Eye Hospital, reported one-year results showing Avastin dosed on a six-week schedule provided significant visual improvement compared to standard therapy. Read more
|
|
At the 2009 SOE Congress, Ursula Schmidt-Erfurth, MD, presented 12-month results from MONT BLANC, the first controlled study to evaluate the safety, efficacy and re-treatment rates of Visudyne and Lucentis as a combination therapy for wet AMD vs. Lucentis monotherapy. She said the results confirm that a lower number of treatments can be used with combination therapy without compromising good visual acuity results gained from Lucentis alone. Read more
|
|
|
|
|
|